Virginia Retirement Systems Et Al Iovance Biotherapeutics, Inc. Transaction History

Virginia Retirement Systems Et Al

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jul 11, 2023	SELL	$5.53 - $8.22 $38,157 - $56,718	-6,900 Reduced 38.12%	11,200 $68,000
Q4 2022 May 17, 2023	SELL	$5.62 - $10.0 $45,522 - $81,000	-8,100 Reduced 30.92%	18,100 $116 Million
Q3 2022 May 16, 2023	BUY	$9.53 - $13.11 $249,685 - $343,482	26,200 New	26,200 $251 Million
Q2 2021 Aug 13, 2021	SELL	$16.33 - $33.07 $129,006 - $261,253	-7,900 Closed	0 $0
Q1 2021 Apr 30, 2021	SELL	$28.67 - $52.59 $48,739 - $89,403	-1,700 Reduced 17.71%	7,900 $250,000
Q4 2020 Feb 16, 2021	BUY	$28.04 - $50.26 $11,216 - $20,104	400 Added 4.35%	9,600 $445,000
Q3 2020 Nov 12, 2020	SELL	$27.75 - $36.3 $263,625 - $344,850	-9,500 Reduced 50.8%	9,200 $303,000
Q2 2020 Aug 12, 2020	SELL	$27.21 - $41.0 $51,699 - $77,900	-1,900 Reduced 9.22%	18,700 $513,000
Q1 2020 May 12, 2020	BUY	$19.54 - $38.85 $5,862 - $11,655	300 Added 1.48%	20,600 $617,000
Q4 2019 Jan 27, 2020	BUY	$17.95 - $29.41 $364,385 - $597,023	20,300 New	20,300 $562,000

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.35B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

Stay updated on Virginia Retirement Systems Et Al with notifications on news.